Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours

被引：6

作者：

Bazhenova, L. ^{[1
]}

Liu, S. V. ^{[2
]}

Lin, J. J. ^{[3
]}

Lu, S. ^{[4
]}

Drilon, A. ^{[5
]}

Chawla, S. P. ^{[6
,7
]}

Fakih, M. ^{[8
]}

Krzakowski, M. ^{[9
]}

Paz-Ares, L. ^{[10
]}

Blakely, C. ^{[11
]}

Buchschacher, G. L., Jr. ^{[12
]}

Cassier, P. ^{[13
]}

Fan, Y. ^{[14
]}

Folprecht, G. ^{[15
]}

McCallum, S. ^{[16
]}

Pitcher, B. ^{[17
]}

Chen, D. ^{[18
]}

Freund, R. ^{[19
]}

Springfeld, C. ^{[20
]}

机构：

[1] Univ Calif San Diego, Moores Canc Ctr, Dept Med, San Diego, CA 92103 USA

[2] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA

[3] Massachusetts Gen Hosp, Dept Hematol Oncol, Canc Ctr, Boston, MA 02114 USA

[4] Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

[5] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Sarcoma Oncol Ctr, Santa Monica, CA USA

[8] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

[9] Maria Sklodowska Curie Inst, Dept Lung & Chest Canc, Ctr Oncol, Warsaw, Poland

[10] Univ Complutense Ciberonc, Hosp Univ 12 Octubre, Dept Med Oncol, CNIO H12o Lung Canc Clin Res Unit, Madrid, Spain

[11] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[12] Los Angeles Med Ctr, Dept Hematol Oncol, Kaiser Permanente Southern Calif, Los Angeles, CA USA

[13] Ctr Leon Berard, Dept Med, Lyon, France

[14] Zhejiang Canc Hosp, Med Dept Thorac Oncol, Hangzhou, Peoples R China

[15] Univ Hosp Carl Gustav Carus, Univ Canc Ctr, Med Dept Unit Med Oncol, Dresden, Germany

[16] Genentech Inc, Medicat Safety & Risk Management, San Francisco, CA 94080 USA

[17] F Hoffmann La Roche Ltd, Stat Sci, Mississauga, ON, Canada

[18] Genentech Inc, Clin Sci, San Francisco, CA 94080 USA

[19] F Hoffmann La Roche Ltd, Med Oncol, Basel, Switzerland

[20] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

533P

引用

页码：S598 / S599

页数：2

共 50 条

[21] Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases
Paz-Ares, L.
Dziadziuszko, R.
Drilon, A.
John, T.
Krebs, M.
Demetri, G.
Shaw, A.
Siena, S.
Wolf, J.
Farago, A.
Simmons, B.
Ye, C.
Huang, X.
Doebele, R.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S305 - S305
[22] Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors or ROS1-Positive NSCLC with CNS Metastases
Paz-Ares, Luis
Dziadziuszko, Rafal
Drilon, Alexander
John, Thomas
Krebs, Matthew
Demetri, George
Shaw, Alice T.
Siena, Salvatore
Wolf, Juergen
Farago, Anna F.
Simmons, Brian
Pitcher, Bethany
Huang, Xinhui
Doebele, Robert
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 235 - 235
[23] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)
Doebele, R. C.
Drilon, A.
Paz-Ares, L.
LANCET ONCOLOGY, 2020, 21 (07): : E341 - E341
[24] Clinical and analytic validation of FoundationOne CDx™ for NTRK fusion-positive solid tumors in patients treated with entrectinib
Fabrizio, David
Milbury, Coren
Yip, Wai-Ki
Yilmazel, Bahar
Bai, Xiaobo
Liao, Juan
Smith, David
Burns, Christine
Vietz, Christine
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[25] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)
Doebele, R. C.
Drilon, A.
Paz-Ares, L.
LANCET ONCOLOGY, 2020, 21 (02): : E70 - E70
[26] Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline
Dziadziuszko, R.
Siena, S.
Tan, D. S. W.
Cho, B. C.
Ahn, M-J.
Goto, K.
Garrido-Lopez, P.
Farago, A. F.
Loong, H. H. F.
Tosi, D.
John, T.
Wolf, J.
Chiu, C-H.
Liu, S. V.
Patel, M. R.
Drilon, A.
Pitcher, B.
Simmons, B.
Doebele, R. C.
ANNALS OF ONCOLOGY, 2020, 31 : S833 - S834
[27] Entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis
Garrido-Laguna, I.
Lonardi, S.
Bazhenova, L.
Peeters, M.
Longo, F.
Sigal, D.
Conkling, P.
Duffaud, F.
Klingbiel, D.
Bordogna, W.
Ciardiello, F.
ANNALS OF ONCOLOGY, 2022, 33 : S370 - S371
[28] Characteristics and outcomes of patients (pts) with NTRK fusion-positive (NTRK plus ) metastatic/locally advanced (LA) solid tumours receiving non-TRK inhibitor (TRKi) standard of care (SoC), and prognostic value of NTRK fusions in clinical practice
Demetri, G. D.
Peters, S.
Hibbar, D. P.
Davies, J.
Maund, S. L.
Veronese, L.
Liu, H.
Humblet, O.
Perez, L.
ANNALS OF ONCOLOGY, 2021, 32 : S399 - S399
[29] Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: of response by line of therapy
Liu, S. V.
De Braud, F.
Drilon, A.
Doebele, R. C.
Patel, M. R.
Cho, B. C.
Ahn, M-J.
Chiu, C-H.
Farago, A. F.
Goto, K.
Lee, J.
Ohe, Y.
Ou, S-H. I.
Cassier, P.
Tan, D. S. W.
Otterson, G. A.
Veronese, L.
Osborne, S.
Simmons, B.
Siena, S.
ANNALS OF ONCOLOGY, 2020, 31 : S472 - S473
[30] Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001
Demetri, G. D.
Paz-Ares, L.
Farago, A. F.
Liu, S. V.
Chawla, S. P.
Tosi, D.
Kim, E. S.
Blakely, C. M.
Krauss, J. C.
Sigal, D.
Bazhenova, L.
John, T.
Besse, B.
Wolf, J.
Seto, T.
Chow-Maneval, E.
Multani, P. S.
Johnson, A.
Simmons, B.
Doebele, R. C.
ANNALS OF ONCOLOGY, 2018, 29 : 175 - 175

← 1 2 3 4 5 →